Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer
Completed
Conditions studied: Breast Cancer
In brief
The purpose of this study is to learn why certain drugs stop working in patients.In lab studies, tumors become resistant in several ways. Specific molecules seem to change and this may be why therapy stops working. However, we do not know if the same molecules change in patients. This study is being done to see if they do change. If we learn more about how patients become resistant, we may be able to offer better treatment in the future.
Key facts
- Study ID
- NCT00897702
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 269
- Starts
- 2007-01-09
- Expected to finish
- 2026-01-23
- Last updated by the study team
- 2026-01-28
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- All patients:
- Diagnosed with breast cancer.
- Patient must be able to consent to a biopsy
- Patient must be able to safely undergo a secondary biopsy, if needed.
- Cohort 1
- Patients who previously received treatment with anti-HER2 therapy (including trastuzumab, pertuzumab, TDM1, lapatinib, neratibin, or DS8201) as part of adjuvant chemotherapy and now have progressive or recurrent breast cancer or, patients who previously (or currently) received anti-HER2 therapy as part of a regimen for metastatic breast cancer and subsequently experienced.
- Evidence of disease progression or recurrence after prior therapy (e.g. radiologic progression by RECIST criteria or new metastasis).
- Prior tumor biopsy (may be original) defined as HER2+ by amplification by FISH (>1.9 gene copy number) or IHC 3+.
- Cohort 2
- Patients who previously received treatment with hormonal therapy (including aromatase inhibitors or SERMs or SERDs) as a part of adjuvant therapy and now have progressive or recurrent breast cancer or patients who previously (or currently) receive hormonal therapy as part of a regimen for metastatic breast cancer and subsequently experienced evidence of disease progression.
- Cohort 3
- Patients not eligible for Cohorts 1 or 2.
You may not qualify if…
- Patients who are unable to consent to a biopsy.
- Patients for whom a repeat biopsy would be medically unsafe
Where it is running
- Memorial Sloan Kettering Basking Ridge (Consent only) — Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Consent only) — Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Consent only) — Montvale, New Jersey, United States
- Memorial Sloan Kettering Commack (Consent only) — Commack, New York, United States
- Memorial Sloan Kettering Westchester (Consent only) — Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Memorial Sloan Kettering Nassau (Consent only) — Uniondale, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.